The Pan American Health Organization
Promoting Health in the Americas

 Safe Hospitals

Health Surveillance & Disease Prevention & Control — Communicable Diseases: 
Acute Respiratory Infections - Anthrax - Antimicrobial Resistance - Campylobacter - Chagas -
Cholera - Dengue - Diarrheal/Enteric Diseases - Disease Outbreak News -
Emerging/Reemerging Diseases - Filariasis - Hantavirus - InfluenzaAvian |  Pandemic |  Seasonal - International Health Regulations - Leishmaniasis - Leprosy - Malaria -
Neglected Diseases - Parasitic Diseases - Rabies - Research - Salmonella - Shigella - Smallpox -
Tuberculosis - West Nile Virus  - Yellow Fever  -
Health Analysis & Statistics - Chronic Diseases - Veterinary Public Health


Health Surveillance and Disease Management / Communicable Diseases / Parasitic and Neglected Diseases

Lymphatic Filariasis Elimination in the Americas:

6th Regional Program Managers' Meeting, 5th Regional Program Review Group Meeting

(San José, Costa Rica, 25–27 October 2005)
LF Meeting 2005

Full Meeting Proceedings   |   Cover

Part I: 6th Regional Program Managers' Meeting (PMM) (25–26 October 2005)

(PDF report of 152 pp plus 21 PowerPoint presentations)

Objectives: One of the objectives of the meeting was to give official recognition by PAHO of the achievements of the three countries that had apparently eliminated transmission of LF within their borders (Costa Rica, Suriname, and Trinidad & Tobago). Costa Rica was commended for its great progress over the last few decades in the fight against LF. Letters of commendation would be awarded to declare PAHO's recognition and satisfaction with the great strides made in the three countries to eliminate transmission of the disease.

Agenda: The meeting agenda included presentations on the advances of the four countries in the Region that still had LF transmission focal points (Brazil, Dominican Republic, Guyana, and Haiti). The meeting group took advantage of the opportunity to hear about program achievements made in the region over the past year, as well as country plans for future work, and that the agenda would include several technical sessions on various program themes, such as disease control and monitoring.

   Table of Contents (PDF, 2 pp, 11 Kb)

  1. Opening & Welcome (PDF, 4 pp, 20 Kb)
    • Inaugural Address
  2. Introduction, Orientation, & Review of Agenda (PDF, 6 pp, 31 Kb)
    • Agenda
  3. Country Presentations: 2005 Progress Reports and 2006 Plan of Action Overviews (text chapters in PDF and corresponding slideshows)
    • Costa Rica: The Filariasis Elimination Program, History and Highlights
      (PDF, 14 pp, 1310 Kb   |   PowerPoint, 51 slides, 5046 Kb: English   |   español)
    • Dominican Republic: The Filariasis Elimination Program—Challenges of Coverage, Scaling Up, and Integration (PDF, 9 pp, 345 Kb   |   PowerPoint, 14 slides, averaging 1500 Kb: English   |   español)
    • Haiti: The Filariasis Elimination Program—Scaling Up MDA and Incorporating DEC-Salt Strategy
      (PDF, 13 pp, 9598 Kb   |   PowerPoint, 28 slides, 4369 Kb)
    • Brazil   (3 text chapters listed below in PDF: 16 pp, 933 Kb)
      • The Filariasis Elimination Program: Urban Challenges, Focal Elimination and Its Verification (PowerPoint, 17 slides, 125 Kb)
      • Recent Progress in Epidemiological Situation & Morbidity Survey in Maceió
        (PowerPoint PDF, 18 slides, 3292 Kb)
      • MDA Upscaling in Recife (in Spanish; PowerPoint PDF, 30 slides, 9647 Kb)
    • Trinidad & Tobago: The Filariasis Elimination Program (PDF, 3 pp, 129 Kb   |   PowerPoint, 30 slides, 231 Kb)
  4. Special Topic: Reports from Key Partners in the Americas (PDF, 20 pp, 411 Kb)
    • GPELF: An Overview of the Global Program for the Elimination of LF: Progress, Financing, & Directions (PowerPoint, 27 slides, 4078 Kb)
    • GAELF: Global Alliance for the Elimination of Lymphatic Filariasis: Update from the Global Alliance Executive Group (PowerPoint, 13 slides, 319 Kb)
    • GSK: Contributions & Challenges (PowerPoint, 5 slides, 537 Kb)
    • Update from the LF Support Centre, Liverpool School of Tropical Medicine (PowerPoint, 10 slides,
      455 Kb)
  5. Special Topic: Decision-Making (PDF, 18 pp, 1014 Kb)
    • Dominican Republic PELF: Integrating an Elimination Program during Times of Reform (PowerPoint PDF, 21 slides, 490 Kb)
    • A Peek at the Windward Islands Research & Education Foundation (WINDREF): Who, Where, When, Why, How? (PowerPoint PDF, 37 slides, 7209 Kb)
  6. Group Guidelines (PDF, 7 pp, 52 Kb)
    • Group 1: Financing the National PELFs: Identifying Alternatives for 2006 & Beyond—The Need for a Regional Plan — the Way Forward (PowerPoint, 12 slides, 149 Kb)
    • Group 2: Developing a Workplan for 2006–2007 to Advance Morbidity Control in the Americas (PowerPoint, 7 slides, 263 Kb)
    • Group 3: Verification of Elimination of LF in Individual Foci: Task for the RPRG? (PowerPoint, 8 slides, 101 Kb)
  7. Group Presentations (PDF, 9 pp, 58 Kb)
    • Group 1: Fundraising (PowerPoint, 4 slides, 121 Kb)
    • Group 2: Advancing Morbidity in the Americas (PowerPoint, 7 slides, averaging 60 Kb: English   |   español)
    • Group 3: Verification of Elimination of LF in Individual Foci: Task for the RPRG? (PowerPoint, 8 slides, 101 Kb)
  8. Special Topic: Operational Research (PDF, 23 pp, 2069 Kb)
    • Application of HealthMapper for Lymphatic Filariasis and Other Neglected Diseases in Brazil: Results after Two Years of Use—Where Should We Go with This Technology in the Americas? (PowerPoint,
      20 slides, 1810 Kb)
    • The Case of Belém, Pará, Brazil: Focal History from Discovery in the 1950s to Elimination after the New Millennium (PowerPoint, 37 slides, 4129 Kb)
  9. Wrap-Up, Highlights, & Perspectives (PDF, 9 pp, 153 Kb   |   PowerPoint, 26 slides, 579 Kb)
  10. Closing Ceremony (PDF, 1 pp, 14 Kb)

Part II: 5th Regional Program Review Group (RPRG) Meeting (27 October 2005)

(PDF report of 114 pp plus 11 PowerPoint presentations)

Objectives: Analyze the Action Plans of Member Countries, generate knowledge to improve technical and scientific capacity, and share practical experiences to be applied to the national programs, in accordance with the RPRG Terms of Reference:

  • Review (country drug) applications and re-applications.
  • Provide guidance to countries in the development of their PELF (Program to Eliminate Lymphatic Filariasis).
  • Review the implementation and progress of the National Programs.
  • Provide technical guidance in theimplementation of the recommendations of the Technical Advisory Group (TAG).
  • Identify operational research issues.
  • Advise PAHO/WHO on matters related to certification of elimination.
  • Advocate and support the Member Countries in seeking political commitment from government.

Agenda: Following the introduction, the most formal topics were addressed first, followed by administrative topics, and then technical-scientific material. There was also a section for presentation and analysis of the National Plans, followed by technical-scientific topics and strategies and opportunities to increase the dynamism of said programs. The final topic was a discussion on resources and other general RPRG matters, followed by presentation and discussion of the Action Points, including an opportunity for members and observers to add to or modify the recommendations.

   Table of Contents (PDF, 2 pp, 11 Kb)

  1. Opening Session (PDF, 7 pp, 39 Kb)
    • Welcome, Introductions, and Expected Meeting Outcomes
    • Designation of Chair, Review of Designations of RPRG Members, and Adoption of Agenda
    • Agenda
  2. Presentation & Analysis of 2006 Plans of Action: National Strategies & Plans for LF Elimination
    (PDF, 27 pp, 304 Kb)
    • Dominican Republic—Program to Eliminate Lymphatic Filariasis (PEFL): 2005 Research & Development (RD) Re-Application (PowerPoint, 5 slides, averaging 260 Kb: English   |   español)
    • Haiti
    • Brazil: No drug application yet; mixed strategies (selective and MDA) (PowerPoint, 10 slides, 270 Kb)
    • Guyana: Program for the Elimination of LF in Guyana (PowerPoint, 22 slides, 1392 Kb)
  3. Technical & Scientific Matters: Surveillance, Monitoring & Evaluation
    • Surveillance and Management of Imported Cases, Residual Morbidity, and Border Areas: Toward Further Lines of Cooperation between Guyana, Suriname, Trinidad & Tobago, & Jamaica (PDF, 2 pp, 24 Kb)
    • Validation of Tools for Verification of Elimination of Transmission
      • PCR & Xenomonitoring Results from Belém & Maceió, Brazil (PDF, 8 pp, 331 Kb; PowerPoint,
        26 slides, 937 Kb)
      • Environmental Risk Index: Use in Evaluation, Monitoring, Intervention, and Surveillance of PELFs (PDF, 10 pp, 963 Kb; PowerPoint,
        17 slides, 5581 Kb)
      • Results of Experimental Comparative Studies of Sensitivity & Specificity of ICT Cards & Og4C3 by CPqAM/Recife in Brazil (PDF, 4 pp, 614 Kb; PowerPoint PDF, 28 slides, 7875 Kb)
    • Current (2005) WHO Guidelines for Monitoring & Epidemiological Assessment of the PELFs at the Implementation Level (PDF, 3 pp, 105 Kb; PowerPoint, 11 slides, 457 Kb)
    • Verification of Interruption of Transmission in Individual Foci: Where Do We Go in the Americas?
      (PDF, 8 pp, 20 Kb)
  4. Resources & Opportunities To Sustain, Scale Up, and Improve National Elimination Programs
    (PDF, 7 pp, 222 Kb)
    • Experiences from OEPA (Onchocerciasis Elimination Program for the Americas) (PowerPoint, 14 slides, 2708 Kb)
  5. Resources for "South-South" Cooperation
    • CPqAM/National Center of Lymphatic Filariasis: Interinstitutional Collaboration (PDF, 4 pp, 572 Kb; Powerpoint PDF, 28 slides, 7875 Kb)
    • Lymphatic Filariasis in Maceió (PDF, 8 pp, 728 Kb; Powerpoint, 26 slides, 5848 Kb)
    • Institute of Dermatology and Skin Surgery (IDCP), Dominican Republic (PDF, 8 pp, 940 Kb; PowerPoint PDF, 72 slides, average size 6000 Kb, split into 2 parts of 36 slides each, rich in photos of the facility and its activities: English 1   |   2   |   español 1   |   2)
    • Comments from the National & Municipal Program Managers: "How To Better Tap Resources To Meet National Program Needs? Comments on Enhancing Cooperation & Coordination (PDF, 2 pp, 45 Kb)
  6. Other RPRG Matters (PDF, 4 pp, 33 Kb)
    • Discussion & Presentation of Drug Forecast Tables
    • Comments from Global Partner GSK
    • Mobilization of Resources for the Americas
  7. Action Points: Discussion, Finalization, & Adoption (PDF, 4 pp, 30 Kb)
  8. Closing Remarks & Adjournment (PDF, 1 pp, ll Kb)

Appendix

  1. List of Participants (PDF, 5 pp, 134 Kb)
  2. Abbreviations (PDF, 3 pp, 115 Kb)
  3. RPRG Membership and Terms of Reference (PDF, 1 pp, 58 Kb)
  4. RPRG Members/Observers (PDF, 2 pp, 72 Kb)
Links to PAHO and WHO Sites on Lymphatic Filariasis (Elephantiasis)

- Meetings: 2004 | 2002 | 2000
- PAHO Parasitic Diseases Page
- PAHO Neglected Diseases Page

- PAHO RPRG Newsletter
- WHO Guidelines
- WHO Lymphatic Filariasis Page

- WHO Partners for Parasite Control (PPC)
- WHO/TDR
- WHO/TDR LF Page